Immunisation schedules for non-replicating nasal vaccines can be made simple by allowing time for development of immunological memory

Vaccine

Volumn 22, Issue 17-18, 2004, Pages 2278-2284

  Bakke, Hilde ^a   Setek, Torhild N ^b   Huynh, Phuong N ^b   Haugen, Inger Lise ^a   Høiby, E Arne ^a   Holst, Johan ^a   Aaberge, Ingeborg S ^a   Haneberg, Bjørn ^a,b  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Mucosal vaccines; Neisseria meningitidis; Outer membrane vesicles (OMVs)

Indexed keywords

MENINGOCOCCUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FECES ANALYSIS; FEMALE; IMMUNIZATION; MEMBRANE VESICLE; MEMORY CELL; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; OUTER MEMBRANE; PRIORITY JOURNAL; SALIVA ANALYSIS;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; FECES; FEMALE; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN A; IMMUNOLOGIC MEMORY; MENINGOCOCCAL VACCINES; MICE; MICE, INBRED BALB C; NEISSERIA MENINGITIDIS; SALIVA; TIME FACTORS; VACCINATION; VACCINES, SUBUNIT;

EID: 2442544484     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.11.040     Document Type: Article

References (21)

1. Haneberg B., Dalseg R., Wedege E., et al. Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect. Immun. 66:1998;1334-1341
2. Oftung F., Næss L.M., Wetzler L., et al. Antigen-specific T-cell responses in humans after intranasal immunisation with a meningococcal serogroup B outer membrane vesicle vaccine. Infect. Immun. 67:1999;921-927
3. Lale A.M., Mason J.D.T., Jones N.S. Mucociliary transport and its assessment: a review. Clin. Otolaryngol. 23:1998;388-396
4. Quaraishi M.S., Jones N.S., Mason J.D.T. The nasal delivery of drugs. Clin. Otolaryngol. 22:1997;289-301
5. Drabick J.J., Brandt B.L., Moran E.F., Saunders N.B., Shoemaker D.R., Zollinger W. Safety and immunogenicity of intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers. Vaccine. 18:1999;160-172
6. Walker R.I. New strategies for using mucosal vaccination to achieve more effective immunisation. Vaccine. 12:1994;387-400
7. Berstad A.K.H., Holst J., Møgster B., Haugen I.L., Haneberg B. A nasal whole-cell pertussis vaccine can induce strong systemic and mucosal antibody responses which are not enhanced by cholera toxin. Vaccine. 15:1997;1473-1478
8. Hordnes K., Tynning T., Brown T.A., Haneberg B., Jonsson R. Nasal immunisation with group B streptococci can induce high levels of specific IgA antibodies in cervicovaginal secretions of mice. Vaccine. 15:1997;1244-1251
9. Dalseg R., Wedege E., Holst J., Haugen I.L., Høiby E.A., Haneberg B. Outer membrane vesicles from group B meningococci are strongly immunogenic when given intranasally to mice. Vaccine. 17:1999;2336-2345
10. Hvalbye B.K.R., Aaberge I.S., Løvik M., Haneberg B. Intranasal immunisation with heat-inactivated Streptococcus pneumoniae protects against systemic pneumococcal infection. Infect. Immun. 67:1999;4320-4325
11. Haugan A., Dao P.X.T., Glende N., et al. Bordetella pertussis can act as adjuvant as well as inhibitor of immune responses to non-replicating nasal vaccines. Vaccine. 22:2003;7-14
12. Bakke H., Lie K., Haugen I.L., et al. Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance. Infect. Immun. 69:2001;5010-5015
13. Fredriksen J.H., Rosenqvist E., Wedege E., et al. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 14:1991;67-80
14. Haneberg B., Kendall D., Amerongen H.M., Apter F.M., Kraehenbuhl J.P., Neutra M.R. Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina, measured by a new method for collection of secretions from local mucosal surfaces. Infect. Immun. 62:1994;15-23
15. Aaberge I.S., Michaelsen T.E., Rolstad A.K., Groeng E.C., Solberg P., Løvik M. Scid-hu mice immunised with a pneumococcal vaccine produce specific human antibodies and show increased resistance to infection. Infect. Immun. 60:1992;4146-4153
16. Høiby E.A., Rosenqvist E., Frøholm L.O., et al. Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey. NIPH Ann. 14:1991;147-156
17. Rosenqvist E., Høiby E.A., Wedege E., et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect. Immun. 63:1995;4642-4652
18. Perkins B.A., Jonsdottir K., Briem H., et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J. Infect. Dis. 177:1998;683-691
19. Haneberg B., Holst J. Can nonliving nasal vaccines be made to work? Expert Rev. Vaccines. 2:2002;227-232
20. Roberts M., Cropley I., Chatfield S., Dougan G. Protection of mice against respiratory Bordetella pertussis infection by intranasal immunisation with P.69 and FHA. Vaccine. 11:1993;866-872
21. Watson JC, Peter G. General immunization practices. In: Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. London: WB Saunders Company; 1999. p. 47-73.